CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure Natriuretic Peptide-Guided Heart Failure Therapy After the GUIDE-IT Study Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel Cardiac Resynchronization Therapy in Inotrope-Dependent Heart Failure Patients - A Systematic Review and Meta-Analysis Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators - The RAID Trial

Review Article2017 Jun 13;69(23):2845-2861.

JOURNAL:J Am Coll Cardiol. Article Link

Left Ventricular Assist Devices for Lifelong Support

Pinney SP, Anyanwu AC, Lala A et al. Keywords: cardiothoracic surgery; heart failure; hemocompatibility

ABSTRACT


Continuous-flow left ventricular assist devices (LVADs) have revolutionized advanced heart failure care. These compact, fully implantable heart pumps are capable of providing meaningful increases in survival, functional capacity, and quality of life. Implantation volumes continue to grow, but several challenges remain to be overcome before LVADs will be considered as the therapy of choice for all patients with advanced heart failure. They must be able to consistently extend survival for the long term (7 to 10 years), rather than the midterm (3 to 5 years) more typical of contemporary devices; they must incorporate design elements that reduce shear stress and avoid stasis to reduce the frequent adverse events of bleeding, stroke, and pump thrombosis; and they must become more cost-effective. The advancements in engineering, implantation technique, and medical management detailed in this review will highlight the progress made toward achieving lifelong LVAD support and the challenges that remain.